Surgical Innovations Group (LSE:SUN) FCF Margin %: 12.86% (As of Dec. 2025) — 599% Above Median


What is Surgical Innovations Group FCF Margin %?

Surgical Innovations Group LSE:SUN FCF Margin % is 12.86% as of Dec. 2025, which is 599% above its 10-year median of 1.84. The stock has 2 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Surgical Innovations Group ranks better than 57.42% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Surgical Innovations Group's Free Cash Flow for the six months ended in Dec. 2025 was £0.70 Mil. Surgical Innovations Group's Revenue for the six months ended in Dec. 2025 was £5.46 Mil. Therefore, Surgical Innovations Group's FCF Margin % for the quarter that ended in Dec. 2025 was 12.86%.

As of today, Surgical Innovations Group's current FCF Yield % is 7.72%.

The historical rank and industry rank for Surgical Innovations Group's FCF Margin % or its related term are showing as below:

LSE:SUN' s FCF Margin % Range Over the Past 10 Years
Min: -11.94   Med: 1.84   Max: 33.86
Current: 2.95

During the past 13 years, the highest FCF Margin % of Surgical Innovations Group was 33.86%. The lowest was -11.94%. And the median was 1.84%.

LSE:SUN's FCF Margin % is ranked better than
57.42% of 815 companies
in the Medical Devices & Instruments industry
Industry Median: -0.03 vs LSE:SUN: 2.95

Surgical Innovations Group FCF Margin % Related Terms

Surgical Innovations Group FCF Margin % Historical Data

* Premium members only.

The historical data trend for Surgical Innovations Group's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surgical Innovations Group FCF Margin % Chart

Surgical Innovations Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.94 -5.22 -2.40 -3.42 2.95

Surgical Innovations Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.03 -11.71 5.44 -5.86 12.86

LSE:SUN vs ABT, SYK, MDT: FCF Margin % Comparison

For the Medical Devices subindustry, Surgical Innovations Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Surgical Innovations Group FCF Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surgical Innovations Group's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Surgical Innovations Group's FCF Margin % falls into.


Surgical Innovations Group FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Surgical Innovations Group's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=0.342/11.602
=2.95 %

Surgical Innovations Group's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=0.702/5.457
=12.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 12.86% mean?
Surgical Innovations Group (LSE:SUN) has a FCF Margin % of 12.86% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Surgical Innovations Group and its competitors. This is 599% above median its historical median of 1.84. According to the industry distribution chart, Surgical Innovations Group ranks #347 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 42.6%.
Is Surgical Innovations Group's FCF Margin % too high?
Surgical Innovations Group's current FCF Margin % of 12.86% is 599% above median its 10-year median of 1.84. Based on the distribution chart, Surgical Innovations Group ranks #347 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Surgical Innovations Group's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Surgical Innovations Group ranks #347 out of 815 companies for FCF Margin %. This puts Surgical Innovations Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Surgical Innovations Group and its competitors. Surgical Innovations Group's current FCF Margin % is 12.86%, which is 599% above median its own 10-year median of 1.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Innovations Group stock overvalued right now?
Based on GuruFocus' analysis, Surgical Innovations Group (LSE:SUN) is currently considered Possible Value Trap. The stock's GF Value™ is £0.01, compared to a current price of £0.00 — trading 52.5% below its estimated fair value. The current FCF Margin % is 12.86%, which is 599% above median its 10-year median of 1.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Surgical Innovations Group (LSE:SUN), the current FCF Margin % is 12.86% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Surgical Innovations Group Business Description

Address Clayton Wood House, 6 Clayton Wood Bank, Leeds, GBR, LS16 6QZ
Surgical Innovations Group PLC is involved in the design, development, manufacture, and sale of devices for use in minimally invasive surgery (SI Brand), along with its label products through original equipment manufacturer (OEM) relationships, including precision engineering markets (PE). The Company's operating segments are SI Brand, OEM, and Distribution. The majority of its revenue is generated from the SI Brand segment, which is involved in the research, development, manufacture, and distribution of SI-branded minimally invasive devices. Geographically, the group derives a majority of its revenue from the United Kingdom, followed by Europe, the United States, the Asia-Pacific region, and the Rest of the world.